No Association between Dopamine D4 Receptor Gene –521 C/T Polymorphism and Tardive Dyskinesia in SchizophreniaLee H.-J.a, b · Kang S.-G.a · Choi J.-E.a, b · Paik J.-W.a · Kim Y.-K.a, b · Kim S.-H.a · Lee M.-S.a, b · Joe S.-H.a · Jung I.-K.a · Kim L.a
aDepartment of Psychiatry, and bDivision of Brain Korea 21 Biomedical Science, Korea University College of Medicine, Seoul, South Korea
Do you have an account?
- Rent for 48h to view
- Buy Cloud Access for unlimited viewing via different devices
- Synchronizing in the ReadCube Cloud
- Printing and saving restrictions apply
Rental: USD 8.50
Cloud: USD 20.00
Tardive dyskinesia (TD) is a long-term adverse effect of antipsychotics. We evaluated whether a candidate functional polymorphism of the dopamine D4 receptor (DRD4) gene is associated with drug-induced TD in 209 Korean schizophrenic patients with TD (n = 83) and without TD (n = 126) who were matched for antipsychotic drug exposure and other relevant variables. There was no significant association of the genotype and allele frequencies determined by the –521 C/T SNP of DRD4 between TD and non-TD patients. In addition, there was no significant difference in terms of total Abnormal Involuntary Movement Scale scores among the 3 genotype groups. Within the limitations imposed by the size of the clinical sample, these findings suggest that the DRD4 –521 C/T SNP does not contribute significantly to the risk for TD.
© 2007 S. Karger AG, Basel
- Kane JM, Smith JM: Tardive dyskinesia: prevalence and risk factors, 1959 to 1979. Arch Gen Psychiatry 1982;39:473–481.
- Sachdev PS: The current status of tardive dyskinesia. Aust NZ J Psychiatry 2000;34:355–369.
- Tamminga CA, Dale JM, Goodman L, Kaneda H, Kaneda N: Neuroleptic-induced vacuous chewing movements as an animal model of tardive dyskinesia: a study in three rat strains. Psychopharmacology (Berl) 1990;102:474–478.
- Yassa R, Ananth J: Familial tardive dyskinesia. Am J Psychiatry 1981;138:1618–1619.
- Tarsy D, Baldessarini RJ: The pathophysiologic basis of tardive dyskinesia. Biol Psychiatry 1977;12:431–450.
Meltzer HY: An overview of the mechanism of action of clozapine. J Clin Psychiatry 1994;55(suppl B):47–52.
- Casey DE, Gerlach J, Magelund G, Christensen TR: gamma-Acetylenic GABA in tardive dyskinesia. Arch Gen Psychiatry 1980;37:1376–1379.
- Chen CH, Wei FU, Koong FJ, Hsiao KJ: Association of TaqI A polymorphism of dopamine D2 receptor gene and tardive dyskinesia in schizophrenia. Biol Psychiatry 1997;41:827–829.
- Chong SA, Tan EC, Tan CH, Mythily, Chan YH: Polymorphisms of dopamine receptors and tardive dyskinesia among Chinese patients with schizophrenia. Am J Med Genet B Neuropsychiatr Genet 2003;116:51–54.
- Steen VM, Lovlie R, MacEwan T, McCreadie RG: Dopamine D3 receptor gene variant and susceptibility to tardive dyskinesia in schizophrenic patients. Mol Psychiatry 1997;2:139–145.
- Segman R, Neeman T, Heresco-Levy U, Finkel B, Karagichev L, Schlafman M, Dorevitch A, Yakir A, Lerner A, Shelevoy A, Lerer B: Genotypic association between the dopamine D3 receptor and tardive dyskinesia in chronic schizophrenia. Mol Psychiatry 1999;4:247–253.
- Lerer B, Segman RH, Fangerau H, Daly AK, Basile VS, Cavallaro R, Aschauer HN, McCreadie RG, Ohlraun S, Ferrier N, Masellis M, Verga M, Scharfetter J, Rietsche lM, Lovlie R, Levy UH, Meltzer HY, Kennedy JL, Steen VM, Macciardi F: Pharmacogenetics of tardive dyskinesia: combined analysis of 780 patients supports association with dopamine D3 receptor gene Ser9Gly polymorphism. Neuropsychopharmacology 2002;27:105–119.
- Rietschel M, Krauss H, Muller DJ, Schulze TG, Knapp M, Marwinski K, Maroldt AO, Paus S, Grunhage F, Propping P, Maier W, Held T, Nothen MM: Dopamine D3 receptor variant and tardive dyskinesia. Eur Arch Psychiatry Clin Neurosci 2000;250:31–35.
- Lattuada E, Cavallaro R, Serretti A, Lorenzi C, Smeraldi E: Tardive dyskinesia and DRD2, DRD3, DRD4, 5-HT2A variants in schizophrenia: an association study with repeated assessment. Int J Neuropsychopharmacol 2004;7:489–493.
- Segman RH, Goltser T, Heresco-Levy U, Finkel B, Shalem R, Schlafman M, Yakir A, Greenberg D, Strous R, Lerner A, Shelevoy A, Lerer B: Association of dopaminergic and serotonergic genes with tardive dyskinesia in patients with chronic schizophrenia. Pharmacogenomics J 2003;3:277–283.
- Srivastava V, Varma PG, Prasad S, Semwal P, Nimgaonkar VL, Lerer B, Deshpande SN, BK T: Genetic susceptibility to tardive dyskinesia among schizophrenia subjects. IV. Role of dopaminergic pathway gene polymorphisms. Pharmacogenet Genomics 2006;16:111–117.
- Okuyama Y, Ishiguro H, Toru M, Arinami T: A genetic polymorphism in the promoter region of DRD4 associated with expression and schizophrenia. Biochem Biophys Res Commun 1999;258:292–295.
- Okuyama Y, Ishiguru H, Nankai M, Shibuya H, Watanabe A, Arinami T: Identification of a polymorphism in the promoter region of DRD4 associated with the human novelty seeking personality trait. Mol Psychiatry 2000;5:64–69.
- Ronai Z, Szekely A, Nemoda Z, Lakatos K, Gervai J, Staub M, Sasvari-Szekely M: Association between novelty seeking and the –521 C/T polymorphism in the promoter region of the DRD4 gene. Mol Psychiatry 2001;6:35–38.
- Lee HJ, Lee HS, Kim YK, Kim SH, Kim L, Lee MS, Joe SH, Jung IK, Suh KY, Kim S: Allelic variants interaction of dopamine receptor D4 polymorphism correlate with personality traits in young Korean female population. Am J Med Genet B Neuropsychiatr Genet 2003;118:76–80.
Han OS, Hong JP: Structured Clinical Interview for DSM-IV Axis I Disorder – Korean Version. Seoul, Hana Medical Publishing, 2000.
American Psychiatric Association: Diagnostic and Statistical Manual of Mental Disorders, ed 4. Washington, American Psychiatric Press, 1994.
Stoll AL: The Psychopharmacology Reference Card. Antipsychotic Treatment Guide. Belmont, McLean Hospital, 1998.
- Schooler NR, Kane JM: Research diagnosis for tardive dyskinesia. Arch Gen Psychiatry 1982;39:486–487.
Guy W: ECDEU Assessment Manual for Psychopharmacology, rev ed. Washington, Department of Health, Education and Welfare, 1976.
- Kay SR, Fiszbein A, Opler LA: The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull 1987;13:261–276.
- Ronai Z, Barta C, Guttman A, Lakatos K, Gervai J, Staub M, Sasvari-Szekely M: Genotyping the –521C/T functional polymorphism in the promoter region of dopamine D4 receptor (DRD4) gene. Electrophoresis 2001;22:1102–1105.
- Binder RL, Kazamatsuri H, Nishimura T, McNiel DE: Smoking and tardive dyskinesia. Biol Psychiatry 1987;22:1280–1282.
- Yassa R, Lal S, Korpassy A, Ally J: Nicotine exposure and tardive dyskinesia. Biol Psychiatry 1987;22:67–72.
- Andersson K, Fuxe K, Agnati LF: Effects of single injections of nicotine on the ascending dopamine pathways in the rat: evidence for increases of dopamine turnover in the mesostriatal and mesolimbic dopamine neurons. Acta Physiol Scand 1981;112:345–347.
- Cadet JL, Lohr JB, Jeste DV: Free radicals and tardive dyskinesia. Trends Neurosci 1986;9:107–108.
- Held T, Weber T, Krausz H, Ahle G, Hager B, Alfter D, Schulze T, Knapp M, Maier W, Rietschel M: Clinical characteristics of patients with tardive dyskinesias. Fortschr Neurol Psychiatr 2000;68:321–331.
- Chouinard G: Interrelations between psychiatric symptoms and drug-induced movement disorder. J Psychiatry Neurosci 2006;31:177–180.
- Shale H, Tanner C: Pharmacological options for the management of dyskinesias. Drugs 1996;52:849–860.
Gorwood P: Genetic association studies in behavioral neuroscience; in Cruzio W, Gerlai R (eds): Molecular Genetic Techniques for Behavioral Neuroscience. Amsterdam, Elsevier, 1999, pp 113–121.
Kim JW: Association study and the population admixture; in Lee MS (ed): Human Neurobehavioral Genetics in the 21st Century – Winter Workshop. Seoul, Korean Society of Biological Psychiatry, 2000.
Article / Publication Details
Copyright / Drug Dosage / DisclaimerCopyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.